PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP)

Historical Holders from Q3 2020 to Q4 2025

Type / Class
Equity / Common stock, par value $0.00001 per share
Symbol
PMVP on Nasdaq
Shares outstanding
52,942,731
Price per share
$1.25
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
37,493,102
Total reported value
$52,489,395
% of total 13F portfolios
0%
Share change
+2,812,393
Value change
+$4,773,977
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
63
Price from insider filings
$1.37
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 9.4% $6,965,407 4,975,291 ORBIMED ADVISORS LLC 23 Oct 2025
TANG CAPITAL MANAGEMENT LLC 8.9% $6,702,907 4,720,357 TANG CAPITAL MANAGEMENT, LLC 16 Sep 2025
BML Investment Partners, L.P. 6.7% $3,258,683 3,466,684 BML Investment Partners, L.P. 31 Dec 2024
Sio Capital Management, LLC 5% -32% $3,691,167 -$1,538,387 2,636,548 -29% Sio Capital Management, LLC 30 Sep 2025
As of 30 Sep 2025, PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) has 63 institutional shareholders filing 13F forms. They hold 37,493,102 shares. of 52,942,731 outstanding shares (71%) .

Top 25 institutional shareholders own 68% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 11% 5,975,291 -7.7% 0.2% $8,365,407
BML Capital Management, LLC 10% 5,292,000 +5.8% 6.8% $7,408,800
TANG CAPITAL MANAGEMENT LLC 9% 4,785,201 0.26% $6,699,281
ArrowMark Colorado Holdings LLC 6.2% 3,301,341 +3.6% 0.09% $4,621,877
Sio Capital Management, LLC 5% 2,636,548 -29% 0.93% $3,691,167
Euclidean Capital LLC 5% 2,627,643 0% 1.5% $3,678,700
VANGUARD GROUP INC 4.1% 2,163,027 +0.44% 0% $3,028,239
ACADIAN ASSET MANAGEMENT LLC 3.9% 2,066,137 0% 0.01% $2,891,000
Stonepine Capital Management, LLC 2.6% 1,370,139 +62% 1.6% $1,918,195
BlackRock, Inc. 2.1% 1,104,140 -3.2% 0% $1,545,795
MARSHALL WACE, LLP 1.2% 612,626 0% $857,677
Aldebaran Capital, LLC 0.95% 504,128 -2.1% 0.65% $705,779
GEODE CAPITAL MANAGEMENT, LLC 0.82% 431,820 -0.2% 0% $604,698
TWO SIGMA ADVISERS, LP 0.79% 417,900 -14% 0% $585,060
JANE STREET GROUP, LLC 0.72% 382,050 0% $534,870
NORTHERN TRUST CORP 0.72% 380,813 +229% 0% $533,138
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.61% 320,653 +115% 0.01% $448,914
Walleye Capital LLC 0.53% 278,459 +258% 0% $389,843
TWO SIGMA INVESTMENTS, LP 0.51% 269,621 -7.5% 0% $377,469
RBF Capital, LLC 0.46% 245,561 0% 0.02% $343,785
Peapod Lane Capital LLC 0.38% 202,784 -55% 0.25% $283,908
BOOTHBAY FUND MANAGEMENT, LLC 0.38% 201,498 0.01% $282,097
CITADEL ADVISORS LLC 0.36% 193,153 -25% 0% $270,414
GOLDMAN SACHS GROUP INC 0.32% 170,802 +80% 0% $239,123
BANK OF AMERICA CORP /DE/ 0.31% 162,496 +458% 0% $227,495

Institutional Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 140,468 $175,585 +$21,720 125% 1
2025 Q3 37,493,102 $52,489,395 +$4,773,977 140% 63
2025 Q2 34,680,709 $36,758,763 -$4,239,299 106% 52
2025 Q1 37,320,031 $40,676,123 -$2,281,128 109% 54
2024 Q4 38,959,310 $58,833,243 -$767,789 151% 70
2024 Q3 39,023,873 $58,153,846 -$2,418,248 149% 73
2024 Q2 40,492,507 $65,596,312 -$3,783,568 162% 92
2024 Q1 42,725,320 $72,627,650 -$11,892,451 170% 96
2023 Q4 16,882 $52,334 310% 1
2023 Q3 54,236,025 $333,005,773 +$15,570,828 614% 103
2023 Q2 51,666,984 $323,502,051 +$3,130,604 626% 103
2023 Q1 51,513,177 $245,718,480 -$16,151,013 477% 111
2022 Q4 54,540,445 $474,497,276 -$38,235,770 870% 112
2022 Q3 58,031,251 $690,573,229 -$34,715,020 1,190% 111
2022 Q2 60,352,324 $859,930,498 +$72,090,452 1,425.01% 101
2022 Q1 50,860,352 $1,058,686,944 +$77,709,829 2,082% 97
2021 Q4 47,118,669 $1,088,471,184 +$8,193,543 2,310.02% 98
2021 Q3 43,990,496 $1,310,909,931 +$46,705,400 2,979.99% 91
2021 Q2 42,211,615 $1,441,945,792 +$79,727,781 3,416% 81
2021 Q1 39,912,275 $1,312,717,295 +$51,997,940 3,289.01% 80
2020 Q4 38,212,089 $2,335,342,669 +$192,149,491 6,151% 72
2020 Q3 31,212,908 $1,098,804,001 +$1,098,803,843 3,550% 51